Clinical Trial Update: Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a Protein Phosphatase 2A inhibitor in recurrent glioblastoma and related gliomas completed, with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma
• Giant Cell Glioblastoma
• Glioblastoma Multiforme
• Glioma
• Oligodendrogliomas

Drugs mentioned

• Protein Phosphatase 2A inhibitor

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Astrocytoma, Grades II, III and IV, Glioblastoma Multiforme | Phase 2 | Status: COMPLETED | Results posted: 2023-11-22